Vapendavir for Common Cold

(Cardinal COPD Trial)

This trial tests the effectiveness and safety of two different doses of an oral medication called vapendavir compared to a placebo for treating the common cold in people with COPD, a lung condition causing breathing difficulties. Researchers will divide participants into three groups to receive either a high dose, a low dose, or a placebo to determine which dose best reduces cold symptoms. Ideal candidates have COPD, have experienced at least one flare-up in the past year, and interact with others at least twice a week. As a Phase 2 trial, this research measures how well the treatment works in an initial, smaller group of people.

The trial does not specify if you need to stop taking your current medications, but if you are on stable COPD maintenance therapy, it should be stable for at least 2 months before joining the trial.

Research has shown that vapendavir is generally safe, as tested in earlier studies. In trials with asthma patients, doses of 264 mg and 528 mg taken twice daily were well-tolerated, and participants had lower levels of the virus in their bodies.

Another study found that vapendavir alleviated symptoms of the common cold caused by rhinovirus. Participants reported milder symptoms and a shorter duration of illness. The treatment was considered safe, with manageable side effects.

Researchers are excited about Vapendavir because it offers a potentially more targeted approach to treating the common cold than current options like decongestants and antihistamines. Unlike these treatments, which mainly focus on alleviating symptoms, Vapendavir works by directly inhibiting the replication of rhinoviruses, the most common cause of colds. This antiviral action could lead to faster relief and potentially shorter illness duration. Additionally, the availability of two dosing options—1000 mg and 500 mg—allows researchers to explore the most effective and safest dose for patients.

Research has shown that vapendavir effectively reduces common cold symptoms, particularly those caused by rhinovirus, in individuals with COPD. Studies have found that vapendavir improves both upper and lower respiratory symptoms and can shorten the illness duration. In this trial, participants will receive either 1000 mg or 500 mg doses of vapendavir, or a placebo, to evaluate its effectiveness. Specifically, in patients with COPD, vapendavir eased breathing problems and sped up recovery from rhinovirus infections. Evidence also suggests that vapendavir works well against all three types of rhinovirus, the main causes of the common cold. This treatment appears promising for managing cold symptoms in people with breathing issues.¹²³⁵⁶